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cord blood (UCB) transplantation (UCBT) have been conducted
and therefore how to choose between these alternative stem cell
sources is not known. Encouraging results of 60% long term
disease-free survival (DFS) or better have been achieved using
unrelated volunteer donors in highly selected patient groups such
as young patients with chronic myelogenous leukemia (CML) who
are transplanted early in their disease course using a 6/6 HLA-
matched donor. However, HLA-mismatch, poor disease risk, older
adult age and non-CML diagnosis are associated with a signiﬁ-
cantly worse outcome after unrelated BMT. Further, recently the
importance of matching for HLA class I as well as class II alleles
has been recognized. However, while matching at 8/8 HLA-A, B,
C and DRB1 (or 10/10 if DQ is included) is associated with
improved outcome, this strategy also reduces the “suitable” donor
pool and can potentially prolong the donor search. The 2002 GAO
report to Congress noted that despite considerable efforts on the
part of the National Marrow Donor Program (NMDP) the num-
ber of transplants facilitated by the NMDP “represent about one
tenth of those we estimate to be in need of unrelated donor
transplants”. As an alternative, UCB offers the potential to extend
the donor pool. However, UCB is limited by cell dose and HLA
match. For example, in a collaborative study led by the New York
Blood Center (NYBC), pediatric recipients of 6/6 UCB units had
a comparable and possibly improved outcome compared to
matched BM, and a comparable outcome if they received 5/6 UCB
units of at least 2.5  107 nucleated cells/kilogram (NC/kg).
Inferior outcome was associated with 5/6 units 2.5  107 NC/kg
or 4/6 units. Notably, in the 4/6 setting, high cell dose could at
least partially compensate for mismatch. Further NYBC analysis of
the outcome of US patients transplanted with myeloablative con-
ditioning and single units has demonstrated that a cell dose2.5
107 NC/kg is required in recipients of 5/6 units (bidirectional
mismatch) to achieve at least 50% survival at one year whereas in
4/6 recipients the cell dose needs to be at least 5  107 NC/kg to
achieve similar outcome. Therefore, not surprisingly, studies of
adult single unit UCBT which have involved 4-5/6 matched units
with a median cell dose of less than 2.5 have demonstrated poor
survival. However, the fact that adult UCBT has had a comparable
outcome to mismatched BM introduces UCB as a valid alternative
to mismatched BMT and calls for new strategies to improve adult
UCBT outcome. One possible strategy is double unit grafts which
have been associated with a 2-year DFS of 60% in 31 patients at
the University of Minnesota. This improved outcome is even
despite the low cell dose of the engrafting unit suggesting intrigu-
ing biology of this approach. Overall the minimum acceptable
criteria for both volunteer donor and UCB grafts have not been
deﬁned. Currently it is reasonable that all patients undergo a
volunteer and UCB search at referral. Donor choice will depend on
the patient diagnosis, the urgency of the transplant, the relative
availability of an adequately matched volunteer versus a UCB unit
of adequate dose and match, physician preference and research
priorities. A volunteer donor may be preferred for a patient with
CML in chronic phase or early accelerated phase and possibly for
other diagnoses such as myeloﬁbrosis or severe aplastic anemia. If
the transplant is urgent (required in less than 6 weeks) UCB has a
clear advantage although a volunteer donor could possibly be
obtained using the NMDP ultra fast search strategy. Acceptable
donors include readily available volunteers that are 7-8/8 matched
(or 9-10/10) and 5-6/6 UCBs 2.5  107 NC/kg or 4/6 5  107
NC/kg. Notably, given the interaction of HLA match and cell
dose, a better UCB unit may be smaller but better matched. If
selected volunteers become unavailable during the search then it is
appropriate to default to UCB to prevent an excessively long
search. In UCB selection issues other than HLA match and dose
are also important. It is ideal to perform conﬁrmatory typing from
an attached segment and given CD34 measurements are not
standardized they should not be used unless two units of similar
match and NC dose are available. Markers for infectious diseases
need to be complete and negative with bacterial and fungal culture
negative at freeze. In the future, greater information concerning
the factors determining outcome after volunteer donor and UCB
transplantation may guide more detailed algorithms for donor
selection.
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AUGMENTATION OF HOMING OF CORD BLOOD STEM CELLS
Broxmeyer H.E., Christopherson II K.W., Hangoc G., Campbell T.B.
Department of Microbiology and Immunology and the Walther Oncology
Center, Indiana University School of Medicine, Indianapolis, IN; Insti-
tute of Molecular Medicine for the Prevention of Human Diseases,
University of Texas Health Science Center, Houston, TX
The ﬁeld of cord blood (CB) transplantation has come quite a
way since its inception and the ﬁrst clinical transplant in October
1988. CB hematopoietic stem (HSC) and progenitor (HPC) cells
have been used to treat a wide variety of genetic disorders and
malignancies. These transplants were possible because the cells
could be cryopreserved for prolonged periods of time and stored in
CB banks for future use. The vast majority of CB transplants have
been performed in children and low weight recipients. Fewer CB
transplants have been done in adults and higher weight individuals
because of the limiting numbers of CB cells that are available for
collection and storage at the birth of babies. A number of proce-
dures have been and are being investigated to enhance the efﬁ-
ciency of CB transplantation for adults. This includes attempts at
ex-vivo expansion of HSC, which has not yet provided a clinical
breakthrough because we don’t know enough of the biology re-
garding stem cell self-renewal and proliferation to truly expand the
HSC. Transplantation of multiple CB units is ongoing with early
clinical success, but this procedure has apparently not greatly
reduced the time to engraftment and only one of the transplanted
CB units seems to survive for longer term engraftment. Not all
mouse HSC home with absolute efﬁciency, effects consistent with
clinical experience in which limiting numbers of cells result in graft
failure. The chemokine stromal cell derived factor-1 (SDF-1)/
CXCL12 and its G protein–linked seven transmembrane span-
ning receptor CXCR4 are involved in chemotaxis, mobilization
and homing of HSC and HSC. CD26 is a cell surface dipepti-
dylpeptidase IV, which can truncate SDF-1/CXCL12. We found
that inhibition or deletion of CD26 on target populations contain-
ing or highly enriched for human CB and human and murine bone
marrow HSC/HPC greatly enhanced the chemotactic responsive-
ness of these cells to SDF-1/CXCL12. Inhibition/deletion of
CD26 in mice was associated with greatly decreased ability to
mobilize HPC with G-CSF. Based on these ﬁnds we hypothesized
that enhancement in homing of HSC to the bone marrow niche
needed for support of the self-renewal and proliferative capacity of
HSC would lead to increased engraftment with limiting numbers
of HSC. We tested this hypothesis, ﬁrst with mouse bone marrow
cells transplanted into lethally irradiated congenic mice in the
setting of non-competitive and also competitive repopulation, each
followed by repopulation in a non-competitive repopulation assay
in lethally irradiated secondary congenic mice. Mouse bone mar-
row donor cells pretreated with CD26 inhibitors Diprotin A (Ile-
Pro-Ile) or Val-Pyr or from CD26 gene knock-out (
/
) mice had
greatly enhanced capacity to home to the bone marrow of recipi-
ents, and this was associated with enhanced engraftment, especially
with dose-limiting numbers of donor cells. Recent work from our
laboratory has found that in vitro inhibition of CD26 on human
CD34 CB cells enhances engraftment of these cells in sublethally
irradiated NOD/SCID mice. These encouraging results with CB
cells suggest that targeting CD26, or other means to enhance
homing/engraftment may be of practical value in a clinical setting
to use limiting numbers of CB HSC for successful transplantation.
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STANDARDIZATION OF CORD BLOOD BANKING PROCEDURES NMDP
NETWORK
Kurtzberg, J., Chell, J., Boo, M., Halet, M., Welte, K. The NMDP
Cord Blood Committee
The National Marrow Donor Program established a cord blood
banking program in 1999. Currently, 14 U.S. banks have joined the
network. A steering committee comprised of bank directors, lab-
oratory supervisors, ethicists, obstetricians, scientists, transplanters
and experts in information technology and regulatory affairs and ad
hoc representation from HRSA and the Navy was established and
meets on a quarterly basis. The purpose of the committee is to
advance cord blood transplantation, improve clinical practice and
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improve patient outcomes. Over the past 18 months, the commit-
tee established common standards for donor recruitment and
screening, cord blood collection, testing, processing, cryopreser-
vation and storage. Eligible cord blood units are listed on the
NMDP donor registry which provides search management, patient
advocacy, conﬁrmatory typing and donor reservations. The Reg-
istry also facilitates distribution of the cord blood units to the
transplant centers, acquires post transplant follow-up data and
provides this data back to the banks for their internal quality
assurance and regulatory reporting requirements. The NMDP also
holds contracts with over 150 transplant centers performing unre-
lated donor transplants, oversees quality and manages billing for
donor procurement. The initial goals of the NMDP banking pro-
gram were to standardize banking practices among member banks.
Five subcommittees were established to address Collections, Qual-
ity Standards, Research, IS/IT, Research and Economies. These
committees established uniform standards for donor selection, col-
lection, processing, testing and banking; criteria for assessing con-
genital anomalies and infant health; an inter-bank proﬁciency pro-
gram; an eye-friendly search report through TRANS Link and
cord blood unit report through CORD Link; improved data out-
comes reporting system and incorporated FDA requirements for
eligibility determination and cGTPs into screening documentation
and labeling. A preliminary research agenda was also developed. A
commitment to apply for mandatory accreditation by 12/05 was
adopted by all member banks. Criteria were established for a cord
blood unit to qualify for listing in the NMDP registry and included
a minimum total nucleated cell count of 9 108 cells with minimal
post processing viability of 90%, enumeration of NRBC and CD34
content, negative bacterial cultures, CFU growth, high resolution
HLA typing for DRB1, testing for hemoglobinopathies and a
minimum of 2 attached segments on the bag in which the unit was
cryopreserved. Collection criteria were standardized to exclude
multiple births; gestational age 34 weeks; a history of cancer,
immune or blood disorders in a ﬁrst degree relative; and the
presence of congenital anomalies associated with congenital blood
disorders on the newborn physical examination. The NMDP in-
ventory now contains approximately 40,000 cord blood units.
Thirty-six percent of the donors represent ethnic minority back-
grounds. Approximately 500 units have been shipped for transplant
to date. Current barriers to collection and banking were reviewed
with their potential solutions. In conclusion, the NMDP banking
network functions as a program within the NMDP employing
common standards for cord blood donors, collection, processing
and storage listing on a single registry in combination with volun-
teer adult donors. Oversight is provided by HRSA. The recent
afﬁliation with the CIBMTR will enable the research agenda.
Efforts over the next years will focus on increasing collections,
establishing protocols for clinical research and obtaining accredi-
tation for all participating banks.
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QUALITY ISSUES IN CORD BLOOD BANKING
McCullough, J. University of Minnesota
As the frequency of umbilical cord blood (UCB) stem cell trans-
plantation has increased, the quality of UCB available in banks is
an important part of the success of the transplants. The AABB and
the Foundation for Accreditation of Cellular Therapy (FACT-
NETCORD) have promulgated standards and regulations pertain-
ing to collection, testing, processing, and banking of UCB for
transplantation. These standards are founded upon quality system
essentials very similar to that of the current Good Manufacturing
Practices (GMPs) and GTPs promulgated by the FDA. For the
most part, the requirements of the standards are similar and pro-
vide a basis for consistency of UCB bank operations. However,
there are some differences that would allow UCB units to be
determined suitable for transplantation in some banks but not
others depending on the source of standards used by that bank.
Also, the requirements have changed over time and so some units
that were suitable for banking at one time may not meet more
contemporary requirements. We used a quality assurance moni-
toring system to evaluate UCB units provided to us for transplant
by UCB banks in the United States and Europe. Of 268 units of
UCB shipped to us for transplantation during a three year period,
151 (56%) had one or more issues potentially related to quality that
required evaluation before a ﬁnal decision regarding their suitabil-
ity for use. There were a total of 246 speciﬁc issues in the 151 units.
The issues involved quality control (54%), medical history (40%),
and labels and documentation (6%). Risks to patients from these
issues were arbitrarily judged to be likely in 10%, potential in 35%,
and unlikely in 55%. The 10% of issues thought likely to affect the
quality of the unit were primarily due to quality control issue such
as transmissible disease test results, potential bacterial contamina-
tion, storage conditions during shipping, and processing methods.
Some of these quality issues such as units with incomplete or
positive tests for transmissible diseases, misleading statements
about the status of testing, tests not done on proper blood samples,
improper UCB unit labels, records and documents lacking proper
unique identifying numbers, or important data related to the UCB
and positive bacterial culture results are examples of failure to use
or follow clear expectations of quality assurance programs. Some of
these units should never have been placed in the useable inventory,
which suggests that despite available standards, some UCB banks
are not operating in conformance with published standards. Con-
siderable variation can also occur even when banks follow applica-
ble standards and quality control programs. This is due to four
factors. First, there are some differences between standards (AABB
and FACT-NETCORD) that would allow UCB units to be de-
termined suitable for transplantation by some banks but not others
depending on which set of standards is being followed. Secondly,
standards and regulations promulgated by AABB, FACT-NET-
CORD, and FDA are not speciﬁc and therefore leave it to the
bank’s discretion to establish criteria for donor acceptance and
quality control test results. Thirdly, standards have changed over
time such that units placed appropriately into the bank in the past
may not meet contemporary standards. Fourthly, each bank may
decide to place individual units into their useable inventory despite
failure to meet that bank’s own criteria as long as the medical
director takes responsibility and documents the reason for deviat-
ing from the banks standard procedures or policies. If standards are
established to assure quality, these four factors mean that different
units within a UCB bank or units from different banks may have
different degrees of quality and, thus, presumably safety. Our
ﬁndings indicate that despite quality programs for UCB promul-
gated by the AABB and FACT-NETCORD, there is considerable
variation in how banks select, process, and control the quality of
units they place into the bank. Some CBUs in banks’ inventory
available for patients do not meet AABB/FACT-NETCORD stan-
dards. Some standards are not speciﬁc and there is a lack of
consensus about a number of issues related to quality. Communi-
cation between banks and transplant centers may not sufﬁciently
timely or effective to allow thoughtful decision-making regarding
the suitability of a speciﬁc CBU for a speciﬁc patient. Our expe-
rience indicates that it is likely that some UCB units presently
being searched in banks in the United States and Europe may not
meet current requirements and/or our desired levels of quality.
Effective and timely communication between the UCB and the
transplant center clinical cell engineering laboratory and transplant
team is essential; present interactions between the banks and trans-
plant centers may not be effective in identifying units that might
pose extra risks and require more unique decision-making. Decisions
about the use of particular units should involve both the transplant
physicians and physicians with expertise in donor suitability.
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A COMPARISON OF PRE- AND POST-CRYOPRESERVATION CD34
COUNTS FROM CORD BLOOD UNITS
Bornstein, R.1, McKenna, D.H.2, Montalbán, M.A.3, De La Cruz, J.4,
Flores, A.I.1, Wagner, J.E.5 1. Madrid Cord Blood Bank, 3. Depart-
ment of Hematology, and 4. Clinical Epidemiology Unit, Hospital 12 de
Octubre, Madrid, Spain; 2. Department of Laboratory Medicine and
Pathology and Blood and Marrow Transplant Program and Stem Cell
Institute, University of Minnesota, Minneapolis, MN
The identiﬁcation of CB units with maximum engraftment po-
tential is an essential issue in CB transplantation. University of
Minnesota (UM) data have shown a high probability of survival in
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